Full-Time

Bioprocess Associate 1

Posted on 8/26/2025

LOTTE BIOLOGICS

LOTTE BIOLOGICS

51-200 employees

GMP CDMO for biologics and ADCs

Compensation Overview

$22.87/hr

+ Shift Differential + Target Bonus

Syracuse, NY, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • High school diploma or equivalent is required.
  • Knowledge of science generally attained through studies resulting in a B.S. in science, engineering, biochemistry, or related discipline or its equivalent is desired.
  • Experience in aseptic technique and mammalian cell culture is desired.
Responsibilities
  • Train for proficiency in the set-up, operation, and cleaning of production and support equipment within assigned functional area(s).
  • Prepare buffers, media, and reagents.
  • Work as a dependable member of a team demonstrating commitment to safety, quality, and compliance.
  • Recognize and report safety, quality, and maintenance events to area management.
  • Maintain accurate documentation.
  • Monitor process parameters and escalate abnormal conditions.
  • Sustain a clean and orderly work environment.
  • Achieve and maintain proficiency through training.
Desired Qualifications
  • Familiarity with general chemistry, microbiology, or clean room operations
  • Prior manufacturing experience
  • Prior experience with cGMP operations or aseptic technique
  • Mechanical aptitude

LOTTE BIOLOGICS provides GMP manufacturing services for biopharmaceuticals, operating a Syracuse, NY campus with a total bioreactor capacity of 40,000 L (eight 5,000 L stainless steel bioreactors) and extensive QC labs and warehousing, supported by regulatory approvals worldwide. The company is expanding into Antibody-Drug Conjugates (ADC) with on-site drug substance production and conjugation, backed by over $100 million invested in ADC modalities, offering an end-to-end service from drug substance manufacturing to ADC conjugation. Looking ahead, it is constructing three advanced bio plants in Songdo, South Korea, each with eight 15,000 L bioreactors plus additional 3,000 L units to support clinical production, aiming for a combined bioreactor capacity exceeding 360,000 L. The overall goal is to become a top-tier global CDMO in the biopharmaceutical industry, delivering therapies to patients worldwide.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

Seoul, South Korea

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • ValGenesis e-Logbook digitizes QC, boosting efficiency since March 2026.
  • Secured first ADC contract with Asia biotech in April 2025.
  • US$100M Syracuse ADC investment attracts clients from China CDMOs.

What critics are saying

  • Songdo completion delays past August 2026 compress 2027 production.
  • ADC facility underutilizes if April 2025 contract terminates.
  • Lonza and Samsung Bioepis erode LOTTE's ADC market share.

What makes LOTTE BIOLOGICS unique

  • LOTTE Biologics offers dual-site manufacturing in Syracuse and Songdo.
  • Proprietary Soluflex Link enables high-potency ADC development.
  • Asimov partnership delivers DNA-to-DS in 8.5 months.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Flexible Work Hours

Target Bonus

Company News

ValGenesis
Mar 17th, 2026
LOTTE Biologics implements ValGenesis e-Logbook solution to modernize QC operations.

LOTTE Biologics implements ValGenesis e-Logbook solution to modernize QC operations. SANTA CLARA, Calif., March 17, 2026 - ValGenesis, Inc., the global leader in enterprise digital validation and compliance solutions, today announced that LOTTE Biologics, a rapidly growing contract development and manufacturing organization (CDMO) headquartered in Seoul, South Korea, has successfully gone live with the ValGenesis e-Logbook solution. The digital logbook management tool transforms operational execution in regulated environments with complete traceability and control. Founded in 2022, LOTTE Biologics entered the pharmaceutical industry with the ambition of becoming a leading global CDMO. The company operates a Bio Campus in Syracuse, New York, and is nearing completion on the construction of a state-of-the-art Bio Campus in Songdo, South Korea, where it is operating a satellite quality control (QC) lab as a precursor to the main facility. As part of its digital transformation journey, LOTTE Biologics has implemented ValGenesis in its satellite QC lab, with plans to extend the platform across its main laboratory and production facilities in the upcoming Songdo Bio Campus. The go-live represents a major milestone in building a fully digital and connected quality ecosystem across the organization. LOTTE Biologics intends to solidify their digital foundation through the implementation and enhancement of enterprise systems, including LIMS, EAM, and EDMS, to support seamless data flow, strengthen consistency, and improve overall operational efficiency. The company is also exploring instrument data automation via the ValGenesis Gateway, which enables direct data capture from laboratory instruments, reducing manual effort, improving accuracy, and providing real-time insights for faster decision-making. The solution replaces paper-based logbooks with real-time digital forms accessible across devices. It supports QR and barcode-based form selection, offline data capture, and no-code configuration to align with standard operating procedures (SOPs). The ValGenesis e-Logbook system ensures regulatory compliance through role-based access, timestamped audit trails, and automated review workflows, and it delivers enterprise-wide visibility when integrated with MES, QMS, LIMS, and CMMS systems. "This project represents more than just a system implementation - it marks a meaningful transformation for LOTTE Biologics," said Hyunjin Cho, IT Team, LOTTE Biologics. "By replacing paper-heavy QC processes with streamlined digital workflows, we have built a more efficient, reliable, and scalable environment that enhances quality management and prepares us for future growth." "We are proud to partner with LOTTE Biologics on this journey toward digital excellence," said Terrance Blackwell, Chief Delivery Officer at ValGenesis, Inc. "The successful go-live underscores our shared commitment to innovation, data integrity, and operational efficiency. With this milestone, LOTTE Biologics takes an important step toward building a fully digital, automated, and compliant R&D-to-manufacturing ecosystem - supporting its vision to become a global leader in biopharmaceutical development and manufacturing." About LOTTE Biologics LOTTE Biologics is a contract development & manufacturing organization (CMDO) delivering integrated biologics and bioconjugate services across the full product lifecycle. Their capabilities encompass phase-appropriate DS manufacturing for mammalian-cell-based biologics, including monoclonal antibodies, fusion proteins, multi-specifics, and integrated ADC manufacturing. Guided by the vision "Possibilities Beyond Limits," LOTTE Biologics works alongside innovators of all sizes to enable efficient scale-up, dependable execution, and the advancement of transformative therapeutic programs. For more information visit: https://www.lottebiologics.com/en About ValGenesis Inc. ValGenesis, Inc., is the global leader in enterprise digital validation. Serving the life sciences industry for nearly two decades, ValGenesis enables companies to digitize their commissioning, qualification, and validation processes through its AI-enabled ValGenesis Smart GxP(TM) platform, which includes solutions for risk management, cleaning validation, continued process verification, and CMC development. ValGenesis helps customers worldwide reduce costs, improve compliance, and accelerate innovation. For more information visit: https://www.valgenesis.com/ For further information, contact: Althea D'Sylva, ValGenesis Communications, +1 510-445-0505 Ex.1026 [email protected] LOTTE Biologics Media Contacts: Baeklae Jo | [email protected] Sangho Lee | [email protected] Kihong Kim | [email protected]

Webarama
Mar 9th, 2026
LOTTE Biologics to Participate in DCAT Week 2026 in New York to Explore Global Partnership Opportunities

LOTTE Biologics to participate in DCAT Week 2026 in New York to explore global partnership opportunities. March 9, 2026 SEOUL, South Korea, March 9, 2026 /PRNewswire/ - LOTTE Biologics announced today that it will participate in DCAT Week 2026, a global pharmaceutical and biotechnology industry event taking place in New York from March 23 to 26, to explore new partnership opportunities and strengthen its global presence in the contract development and manufacturing organization (CDMO) sector. Held annually in New York, DCAT Week is one of the industry's most prominent global gatherings, bringing together pharmaceutical companies, CDMOs, and other life sciences stakeholders to discuss collaboration opportunities and industry trends. During the event, LOTTE Biologics will host a series of meetings at the Lotte New York Palace Hotel, where DCAT Week is held, to engage with potential partners and explore new business opportunities in the global CDMO market, including North America. The company will highlight the synergy between its Syracuse Bio Campus in New York and the Songdo Bio Campus in Incheon, South Korea, which is scheduled for mechanical completion in August 2026 as part of LOTTE Biologics' plan to expand its global manufacturing network. By leveraging the dual-site model across the United States and Korea, the company aims to support global partners with flexible and reliable manufacturing capabilities. LOTTE Biologics will also emphasize the expansion of its service capabilities through strategic collaborations. In particular, through its ongoing collaboration with the U.S.-based cell line development experts Asimov, the company is able to offer end to end DNA to DS services. This collaboration allows for streamlined, unified capabilities with 8.5 month timelines from transfection to drug substance release. "DCAT Week is an important gathering where key decision-makers across the global pharmaceutical and biotechnology industry come together," said a representative from LOTTE Biologics. "Through this participation, we aim to actively explore partnership opportunities with potential clients and continue strengthening our competitiveness in the global market."

Chosun Ilbo
Dec 26th, 2025
Hotel Lotte invests ₩214B in Lotte Biologics to boost senior business synergy

Hotel Lotte will invest 214.4 billion Korean won to acquire a 19.07% stake in Lotte Biologics, aiming to enhance synergy in the senior business sector and stabilise revenue. The hotel company has been expanding its silver industry presence, launching premium senior residence brand VL in 2022 and completing VL Lauher in Busan this year. Lotte Biologics will begin operations next August with Plant 1 at its Songdo Campus in Incheon. The company operates a dual-site system with its Syracuse Campus in the US, positioning itself as a global contract development and manufacturing organisation. Hotel Lotte expects the investment to provide a stable revenue base, offsetting the hotel industry's volatility from economic changes through exposure to the bio industry.

BioSpace
Aug 4th, 2025
LOTTE BIOLOGICS Accelerates Global CDMO Expansion with Dual Manufacturing Bases in North America and Asia, and Next-Generation ADC Modalities

LOTTE BIOLOGICS has invested approximately USD 100 million into its Syracuse Bio Campus to establish advanced ADC production infrastructure, including conjugation suites with capacities of up to 1,000L.

Ten News Network
Apr 24th, 2025
Lotte Biologics wins 1st antibody-drug conjugate deal in Asia

Lotte Biologics has invested US$100 million to build the ADC manufacturing facility within its existing U.S. plant, reports Yonhap news agency.

INACTIVE